<DOC>
	<DOCNO>NCT00658320</DOCNO>
	<brief_summary>The 12 Month Core Study ( CRAD001A1202 ) design evaluate efficacy safety compare concentration-controlled everolimus ( 1.5 mg/day start dose ) reduce dose cyclosporine corticosteroid versus 2 g/day mycophenolate mofetil ( MMF ) standard dose cyclosporine corticosteroid de novo renal transplant recipient . Extension Study ( CRAD001A1202E1 ) : Until 24 month renal transplantation , study design evaluate long-term safety efficacy compare concentration-controlled everolimus reduce dose cyclosporine ( Neoral® ) corticosteroid versus mycophenolate mofetil standard dose Neoral® corticosteroid de novo renal transplant recipient . Beyond 24 month renal transplantation , study design provide everolimus treatment patient everolimus group everolimus approve marketed Japan .</brief_summary>
	<brief_title>Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine de Novo Renal Transplant Adult Recipients Treated With Basiliximab Corticosteroids</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Core Study Male female de novo renal transplant recipient 18 65 year age Patients receive primary cadaveric donor nonhuman leukocyte antigen ( nonHLA ) identical living donor kidney transplant Patients give write informed consent participate study Females capable become pregnant must negative pregnancy test prior randomization . Core Study Patients evidence graft function within 24 hour transplantation exclude Recipients dual kidney transplant Patients recipient multiple solid organ tissue transplant , previously receive organ tissue transplant . Recipients kidneys HLAidentical living related donor Patients recipient ABO incompatible transplant T cell cross match positive transplant . Although Panel Reactive Antibodies ( PRA ) test mandatory , patient whose recent antiHLA Class I PRA &gt; 20 % By CDC ( Complement dependent cytotoxicity ) base assay &gt; 50 % Flow Cytometry ELISA ( Enzyme link immunosorbent assay ) base assay Patients test positive human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , Hepatitis B surface antigen . Laboratory result obtain within 6 month prior randomization acceptable , otherwise test perform within two week prior randomization . Recipients organs donor test positive Hepatitis B surface antigen , HCV HIV exclude Donor organ cold ischemia time &gt; 24 hour Donor age great 65 year Patients platelet count &lt; 100,000/mm baseline transplantation Patients absolute neutrophil count &lt; 1,500/mm³ white blood cell count &lt; 4,500/mm³ baseline transplantation Patients severe hypercholesterolemia ( &gt; 350 mg/dL ; &gt; 9 mmol/L ) hypertriglyceridemia ( &gt; 500 mg/dL ; &gt; 8.5 mmol/L ) . Patients control hyperlipidemia acceptable Patients abnormal liver profile alanine aminotransferase ( ALT ) , Aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) total bilirubin &gt; 3 time upper limit normal ( ULN ) Patients know hypersensitivity either study drug class , excipients Patients treat drug strong inducer inhibitor cytochrome P450 Patients unable take oral medication time randomization Patients receive investigational drug treat nonprotocol immunosuppressive drug treatment within 30 day 5 halflives prior randomization Patients history malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize excised nonmelanomatous skin lesion Patients clinically significant systemic infection time transplant within two week prior transplant Patients history severe diarrhea , active peptic ulcer disease , uncontrolled diabetes mellitus Patients cardiac failure time screening ( rest dyspnea , Grade ≥ 3 accord Old New York Heart Association Classification ( Appendix 7 ) severe cardiac disease determine investigator Patients surgical medical condition , opinion investigator , might significantly alter absorption , distribution , metabolism excretion study medication Patients abnormal physical laboratory finding clinical significance within 2 week prior randomization would interfere objective study Patients history coagulopathy medical condition require longterm anticoagulation would preclude renal biopsy transplantation . ( Low dose aspirin treatment interruption chronic anticoagulant allow ) Females childbearing potential planning become pregnant , pregnant and/or lactating , unwilling use effective mean contraception . Extension Study Patients complete Month 12 visit core study ( include patient discontinue study medication ) Patients give write informed consent participate extension study Extension Study Women childbearing potential planning become pregnant , unwilling use two effective mean contraception , include abstinence judge investigator , surgical sterilization ( e.g . bilateral tubal ligation , hysterectomy ) , hormonal contraception ( implantable , patch , oral ) , barrier method ( male female condom spermicidal gel , diaphragm , sponge , cervical cap ) . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Renal transplantation</keyword>
	<keyword>everolimus</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>cyclosporine</keyword>
	<keyword>corticosteroid</keyword>
	<keyword>basiliximab</keyword>
	<keyword>Banff diagnosis</keyword>
	<keyword>Acute rejection</keyword>
	<keyword>Therapeutic drug monitoring ( TDM )</keyword>
	<keyword>de novo renal transplant recipient</keyword>
</DOC>